Evaporation of Fe and FeS dust in the active stage of the primordial solar nebula, and Fe/S fractionation

The evaporation kinetics of troilite and metallic iron was applied to evaporation of dust particles moving toward the protosun in the turbulent solar nebula. In the calculations, it was assumed that dust particles do not grow by collision, evaporated gas and residual dust are not separated, and dust particles move only radially along the midplane or the surface of the nebula. It was found that evaporation of metallic iron would occur almost in equilibrium both along the midplane and the surface. Troilite could survive to higher temperature than the equilibrium evaporation temperature due to its evaporation kinetics. However, the kinetic effects are not so large, and the incongruent evaporation of troilite is also regarded to occur roughly in equilibrium. The timescales for evaporation of metallic iron and troilite were compared with the timescales for drifts along r-and z-directions and that for coagulation to understand general aspects of the effect of evaporation kinetics. Since the temperature of the surface is lower than that of the midplane, dust particle at the surface can get closer to the sun than those at the midplane. This can cause Fe/S fractionation in a wide range of the nebula if effective solid-gas separation occurred

Interaction Potential for Vibrational-Translational Energy Transfer in Collision between I₂ and Ar

In order to determine the interaction potential parameters for vibrational-translational energy transfer collision between Ar and I₂ excitedby 5145Å line of an Ar⁺ laser, the three dimensional model of Hansen and Pearson is compared with the experimental results of laser induced fluorescence obtained by the method of Steinfeld et al.. In the model, the interaction potential is assumed to be a linear superposition of exponential repulsions between atomic centers and determined by two parameters, i.e., scale size and characteristic length. These are determined to be 0.14 eV and 0.25Å, respectively, from comparison of the theoretical rate coefficient for the energy transfer with the experimental one relative to their dependence on gas temperature

Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5

Onishi R., Ikemoto S., Shiota A., et al. Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5. International Journal of Pharmaceutics 662, 124480 (2024); https://doi.org/10.1016/j.ijpharm.2024.124480.Adenovirus (Ad) vectors based on human adenovirus serotype 5 (Ad5) have attracted significant attention as vaccine vectors for infectious diseases. However, the effectiveness of Ad5 vectors as vaccines is often inhibited by the anti-Ad5 neutralizing antibodies retained by many adults. To overcome this drawback, we focused on human adenovirus serotype 35 (Ad35) vectors with low seroprevalence in adults. Although Ad35 vectors can circumvent anti-Ad5 neutralizing antibodies, vector yields of Ad35 vectors are often inferior to those of Ad5 vectors. In this study, we developed novel Ad35 vectors containing the Ad5 E4 orf 4, 6, and 6/7 or the Ad5 E4 orf 6 and 6/7 for efficient vector production, and compared their properties. These E4-modified Ad35 vectors efficiently propagated to a similar extent at virus titers comparable to those of Ad5 vectors. An Ad35 vector containing the Ad5 E4 orf 4, 6, and 6/7 mediated more efficient transduction than that containing the Ad5 E4 orf 6 and 6/7 in human cultured cells. Furthermore, insertion of an arginine-glycine-aspartate (RGD) peptide in the fiber region of an Ad35 vector containing the Ad5 E4 orf 4, 6, and 6/7 significantly improved the transgene product-specific antibody production following intramuscular administration in mice. The Ad35 vector containing the RGD peptide mediated efficient vaccine effects even in the mice pre-immunized with an Ad5

Pilot study of the optimal protocol of low dose step‐up follicle stimulating hormone therapy for infertile women

Purpose: To evaluate the optimized protocol of low dose follicle‐stimulating hormone (FSH) therapy that has a starting dose of 50 IU/62.5 IU with a small increment dose (12.5 IU) for women with World Health Organization (WHO) II ovulatory disorder and unexplained infertility. Methods: Anovulatory women with WHO group II ovulatory disorder (ovulation induction [OI] patients, n = 29), and with an unexplained infertility (ovarian stimulation [OS] patients, n = 21) were enrolled. The protocol of low dose step‐up FSH therapy was optimized for the starting dose as 50 IU (body mass index [BMI] < 20 group) and 62.5 IU (BMI ≥ 20 group) with the increment dose of 12.5 IU. Study outcomes were ovulation, monofollicular development and other variables. Results: In the OIpatients, the ovulation rate was 100% (BMI < 20 group) and 90.9% (BMI ≥ 20 group). Monofollicular development was 80.0% (BMI < 20) and 77.3% (BMI ≥ 20). The pregnancy rate was 60% (3/5 BMI < 20) and 18.2% (4/22 BMI ≥ 20). There was no multiple pregnancy. In the OSpatients, the ovulation rate was 100%. Monofollicular development was 85.7% (BMI < 20) and 76.6% (BMI ≥ 20). No pregnancy was achieved in the OSpatients. Conclusion: Optimized protocol of low dose FSH therapy setting a starting dose 50 IU/62.5 IU by BMI with an increment dose of 12.5 IU was safe and highly effective in WHO group II anovulatory patients. However, this protocol seemed uneffective for patients with unexplained infertility